标题
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
作者
关键词
-
出版物
Cancers
Volume 13, Issue 11, Pages 2824
出版商
MDPI AG
发表日期
2021-06-07
DOI
10.3390/cancers13112824
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
- (2021) Francesco Schettini et al. npj Breast Cancer
- The Exciting New Field of HER2-Low Breast Cancer Treatment
- (2021) Daniel Eiger et al. Cancers
- Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
- (2021) Aleix Prat et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients
- (2020) G. Travis Clifton et al. CLINICAL CANCER RESEARCH
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
- (2020) Kimberly H. Allison et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond
- (2020) Caterina Marchiò et al. SEMINARS IN CANCER BIOLOGY
- HER2-Low Breast Cancer: Pathological and Clinical Landscape
- (2020) Paolo Tarantino et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
- (2020) Gaia Griguolo et al. Cancers
- HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
- (2019) Gabriel Rinnerthaler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 152OFirst report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)
- (2019) P G Aftimos et al. ANNALS OF ONCOLOGY
- Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
- (2019) Elizabeth A. Mittendorf et al. CLINICAL CANCER RESEARCH
- HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
- (2019) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
- (2019) Louis Fehrenbacher et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- (2018) Jianfang Liu et al. CELL
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
- (2018) Hiroji Iwata et al. JOURNAL OF CLINICAL ONCOLOGY
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
- (2017) Debora Fumagalli et al. JAMA Oncology
- Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas
- (2017) Dezheng Huo et al. JAMA Oncology
- Clinical implications of the intrinsic molecular subtypes of breast cancer
- (2015) Aleix Prat et al. BREAST
- Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer
- (2015) Holm Eggemann et al. ENDOCRINE-RELATED CANCER
- TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
- (2015) Antonio Colaprico et al. NUCLEIC ACIDS RESEARCH
- Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
- (2014) Katherine A. Hoadley et al. CELL
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
- (2014) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer
- (2012) Valentina Rossi et al. ONCOLOGIST
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More